Northrop Grumman Corporation enters the week trading at $558.30, still nursing a 17% one-month decline after a Q1 earnings print that hit investors hard — and with another earnings event just one week away.
The story this past month is overwhelmingly about the April 21 earnings reaction. The stock fell 10.3% on the day and another 12% over the following five sessions, the sharpest post-print move in the recent data. That sell-off dragged the stock well below its prior range and pushed the RSI-14 to a deeply oversold 26.4, one of the most washed-out readings in the sector. The recovery this week has been modest: NOC gained just under 2% on Tuesday but is essentially flat over the five-day window, while peers LMT and RTX added 2.4% and 3.5% respectively. LHX gained 2.3% and even HII bounced 4.9%. NOC is the clear laggard in the group.
Positioning tells a comparatively relaxed story. Short interest barely registers as a variable here — it sits at 1.2% of free float, only fractionally higher than a week ago, with the 90-day trend actually down nearly 5%. The borrow market reflects that: cost to borrow is 0.43%, well off its recent high of around 0.51% from early May, and availability in the lending pool remains extremely loose. This is not a name where short pressure is driving price action. Options do add a small nuance: the put/call ratio at 0.84 is nearly 1.5 standard deviations below its 20-day average of 0.92, meaning call activity has actually picked up relative to puts over the past week — an unusual tilt toward the upside in a stock that's been in freefall.
The Street is processing the damage cautiously. Following the Q1 print, UBS and Citigroup both maintained Buy ratings but cut targets sharply — UBS to $745 from $806, Citigroup to $742 from $807 — while Morgan Stanley trimmed its Overweight target to $745 from $765. Those three moves all landed on April 22–23, right in the wreckage of the earnings sell-off. The overall consensus remains a hold, with 11 hold ratings against four outperform calls and no sells on the tape. The mean implied return potential to analyst targets is 27%, which is either a compelling valuation gap or a reflection of how quickly those targets will migrate lower ahead of the May 20 report. Valuation has cheapened materially: the P/E has contracted by more than four points over 30 days to 19.4x, and price-to-book has fallen nearly a full point to 4.1x. The analyst-recommendation-divergence factor sits at the 92nd percentile — a high reading that flags the gap between where Street targets are and where the stock is trading.
The bull case rests on the classified-work franchise and the B-21 bomber program. Roughly 34% of NOC's sales run through classified contracts, providing a degree of revenue visibility that is hard to replicate elsewhere in the sector. The B-21, Sentinel, missile defense, and munitions pipelines all represent genuine long-duration growth drivers. Bears point to exactly those same programs: B-21 cost overruns and the Sentinel realignment at Space Systems are the clearest near-term margin risks, and the company's rising international mix could push capex higher and pressure free cash flow guidance through 2026. Wells Fargo initiated coverage at Overweight with an $800 target on April 1, a move that looks prescient in its timing but painful in outcome given the subsequent 30% gap between target and current price.
The May 20 print arrives in one week. The last two quarterly reports produced negative one-day moves of 2.5% and 10.3%, so the directional risk from earnings has been skewed to the downside in the recent cycle. Capital Research added 703,940 shares through April 30 — now at 10.7% of shares — and Wellington Management built a position of 1.4 million shares in the same period, both meaningful signals that large institutional buyers see value at these levels. Whether the Q1 reaction was a one-off or the start of a reassessment of the margin outlook is the question the May 20 report will need to answer.
See the live data behind this article on ORTEX.
Open NOC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.